)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Avecho Biotechnology
Avecho Biotechnology (AVE) investor relations material
Avecho Biotechnology Q1 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 TU earnings summary28 Apr, 2026
Executive summary
Exceeded recruitment target for Phase III insomnia trial, randomising 244 patients, 16% above plan, enhancing statistical power for interim analysis.
Interim analysis read-out remains on track for June 2026, with an independent Data Monitoring Board (DMB) overseeing data integrity.
Commercial partnership with Sandoz AG secured for Australia, including milestone payments and tiered royalties on net sales.
Strengthened patent position in the US and EU, supporting global commercialisation efforts.
Financial highlights
Cash balance at 31 March 2026 was $4.3 million.
Operating cash outflows for the quarter were $578K, partially offset by $184K in customer receipts.
$493K invested in research and development during the quarter, focused on the Phase III trial.
Payments to related parties totaled $66K for the quarter.
Outlook and guidance
Interim analysis in June 2026 is expected to de-risk the program and support licensing discussions outside Australia.
Cash runway estimated at 4.89 quarters as of 31 March 2026, supporting ongoing development and operations.
Positive interim results could accelerate commercialisation and value creation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Avecho Biotechnology
- Revenue up 9%, net loss widens, Sandoz licensing deal and $2.5M capital raise highlight year.AVE
H2 20256 Apr 2026 - Phase III CBD insomnia capsule nears interim results, backed by Sandoz for Australian launch.AVENWR Virtual Healthcare Conference25 Mar 2026
- Phase III CBD insomnia trial nears interim analysis; $2.5M raised and key patents allowed.AVEQ4 2025 TU8 Feb 2026
- Phase III insomnia trial advances, cash position strengthened by $2.5M capital raise.AVEQ3 2025 TU31 Oct 2025
- A high-bioavailability CBD capsule for insomnia targets global markets after a major Sandoz deal.AVEInvestor Presentation20 Oct 2025
- Accelerated Phase III trial progress and strong cash position support first-mover CBD ambitions.AVEQ2 2025 TU29 Jul 2025
- Phase III CBD insomnia trial nears interim analysis, aiming for first OTC approval in Australia.AVEStudy Update28 Jul 2025
- Phase III trial progress and strong manufacturing drive Avecho's operational momentum.AVEQ3 2024 TU13 Jun 2025
- Revenue down 30%, net loss widens as R&D ramps up for Phase III CBD insomnia trial.AVEH1 202413 Jun 2025
Avecho Biotechnology
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage